- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Vape Company with Ties to Canadian LPs Fires a Quarter of Staff
Vape pen maker Pax Labs, which is partnered with five Canadian LPs, has announced a 25 percent reduction of its workforce, equivalent to 65 people.
PAX Labs, a vaporizer technology company partnered with several Canadian licensed producers (LPs), has elected to reduce its workforce by approximately 25 percent.
Most recently, PAX Labs formed a partnership with Zenabis Global (TSX:ZENA). It also has relationships with The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF), Aphria (NYSE:APHA,TSX:APHA), Aurora Cannabis (NYSE:ACB,TSX:ACB) and Organigram Holdings (NASDAQ:OGI,TSXV:OGI).
In a statement to the Investing News Network (INN), a PAX Labs spokesperson said the cuts were due to a recent “significant revenue miss” that affected the firm.
“In light of this fact, coupled with evolving business priorities and industry dynamics, we have made the difficult decision to part ways with 65 members of our team, or 25 percent of the organization, effective today,” the statement from PAX Labs explains.
The vape pen company did not indicate how this reduction in its workforce could affect its plans for the Canadian market and its partnerships with Canadian players.
First reported by Marijuana Business Daily, the downsize is linked to the state of the vape market due to the recent health crisis seen in the US linked to vape pens.
PAX Labs’ supply deals in the Canadian marijuana market came recently. Supreme Cannabis, Aphria and Aurora all signed on as brand partners for the company’s PAX Era pen and pod system in June.
“Together, we expect to deliver 7ACRES’ multi-award winning flower extracted into oils exclusively for use in North America’s best-selling premium vaporizer, the PAX Era,” Navdeep Dhaliwal, CEO of Supreme Cannabis, said in a partnership statement at the time.
Supreme Cannabis’ deal is related to the exclusive availability of products from its recreational brand 7ACRES with the PAX Era pen and pod product.
In a statement, PAX Labs, which is based in San Francisco, California, indicated that its LP partners would expand the experience of using PAX Era products.
“As the market grows, we will continue to bring on more brand partners, offering our consumers a selection of products on the PAX Era platform,” said Tim Pellerin, Canadian general manager with PAX Labs, at the time the four deals were announced.
Zenabis linked up with PAX Labs in September. Under the agreement, the Canadian producer will supply cannabis extracts for the same vaporizer device.
“We are pleased to partner with PAX … and to join the other four Canadian LP’s in the launch of PAX Era Pods,” Andrew Grieve, CEO of Zenabis, previously said.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.